Metachromatic leucodystrophy (MLD)
zygous carrier of the arylsulphatase A pseudodeficiency allele. The ring 22 was shown by Southern blotting to be deleted in one copy of the arylsulphatase A gene. Minisatellite analysis showed the extent of the deletion and confirmed the biparental inheritance of chromosome 22 sequences. The carrier status of the parents and the patient's 46,XX,r(22) karyotype complicated the initial diagnosis in this family. However, the causal relationship of the ring 22 and MLD have implications for the recurrence risk in this family. (JMed Genet 1995; 32:787-791) Metachromatic leucodystrophy (MLD) is a neurodegenerative lysosomal storage disease resulting from a deficiency of activity of arylsulphatase A (ASA, EC 3.1.6.1), an enzyme involved in the normal catabolism of cerebroside sulphatide. MLD is characterised by accumulation of cerebroside sulphatide especially in the myelin forming cells of the CNS. 1 The ASA gene has been mapped to chromosome 22q13.3 and its complete sequence determined.2A variety of mutations have been reported.3 In the present context the most significant are the "I" allele4 and the pseudodeficiency allele.5 The infantile onset "I" allele consists of a composite of a G-*A transition at the + 1 position ofintron 2 ("I-1"), a trpl93cys mutation in exon 3 ("I-2"), and a thr391ser in exon 7 ("I-3"). The splicing mutation is the deleterious mutation. The exon 3 "I-2" mutation is usually found in association with "I-I" but has no effect on enzyme activity. The "I-3" is a common polymorphism found in up to 54-4% of the general population.46 ASA pseudodeficiency is a situation where ASA activity is significantly reduced without any clinical or biochemical evidence of disease.7 Pseudodeficiency carriers occur at 10 to 20% in the general population. ASA activity can be reduced to about 15% of normal in homozygotes. A complex of two mutations has been implicated in the pseudodeficiency, a glycosylation site mutation (asp350ser) affecting the third glycosylation site of the enzyme and an A-+G in the first poly A addition signal. 5 The former results in loss of a glycosylation site but appears to have little effect on ASA production or activity. The latter results in up to 80% reduction in ASA activity.
The map location of the ASA gene renders it vulnerable to deletion in chromosome 22 terminal deletions and ring formations. Indeed, several cases of such deletion of the ASA gene have been documented.5" However, the concomitant occurrence of ring 22 and a severe MLD allele has not previously been reported.
We report such a case here. The occurrence of this chromosome rearrangement as one of the alleles in this MLD patient practically eliminates the risk of MLD in future offspring of this family.
Materials and methods

CASE REPORT
This female child was born to non-consanguineous parents. She showed delayed development in her first year and was investigated for deafness at 14 months. Unusual physical features including large ears, high forehead, upward slanting eyes, micrognathia, large extremities, and broad hands with short phalanges were noted at that time. She also had spina bifida occulta with a sacral dimple. Karyotype investigation showed a possible ring chromosome 22 in all cells examined. This was later confirmed in two subsequent karyotype studies. A partial spread of metaphase chromosomes from cultured fibroblasts is shown in fig 1. Neither parent showed the ring 22 formation. Because the child's condition was worsening more rapidly than would be expected from the ring chromosome alone, she was investigated for the possibility ofmetabolic errors. Enzymatic assay of arylsulphatase A in fibroblast extracts gave a diagnosis of MLD when the child was 2 years 3 months. She deteriorated rapidly becoming decerebrate by the age of 2 years 4 months and died at 2 years 10 months.
MATERIALS
Taq polymerase was purchased from Promega. ID 
Restriction enzyme recognition sites were incorporated into primers by MvaI and thus he is a heterozygous carrier of this mutation. The patient's sample appears to be homozygous for the "I-1" mutation; it was totally uncut. However, the mother's sample was completely cut and therefore she does not carry the "I-1" mutation. This suggests that her daughter is probably deleted in one ASA allele and is actually hemizygous for the "I-1" mutation. Further support for this comes from PCR based analyses of the "I-2" and "I-3" polymorphisms and the pseudodeficiency mutations as outlined in table 1. The "I-1 " and "I-2", and the "I-3" and glycosylation mutations can be detected simultaneously (data not shown). The glycosylation mutation can also be identified independently of the "I-3". Results for the poly A signal mutations are shown in fig 2B. The samples from the father and daughter were not cut by RsaI indicating that they were both homozygous negative for the mutation. The mother's sample was partly cut by RsaI indicating that she is a carrier of the mutation. In summary, the father is heterozygous for all three "I" mutations and homozygous negative for the two pseudodeficiency mutations (glycosylation and poly A). The mother is homozygous negative for all three "I" mutations and a heterozygous carrier for the two pseudodeficiency mutations. The patient carries the three "I" mutations but not the two pseudodeficiency mutations. The finding of a pseudodeficiency allele in the mother accounts for her decreased level ofASA enzyme activity. Clearly none of the mother's ASA markers, neither her pseudodeficiency mutations, nor her normal sequence at the sites of the "I" mutations, have been passed to her daughter, consistent with a complete deletion of the gene. Amplification with the primers for the markers D22S315 and TOPIP2 clearly indicated inheritance of unique alleles from both parents in the child. The markers D22S283 and CYP2D also showed probable inheritance from both parents; however a common allele is shared by all three family members. Thus, these markers are proximal to the breakpoints involved in the ring formation. These data, in conjunction with the "I" allele inheritance pattern, confirm that there is biparental inheritance of chromosome 22 sequences and that the ring with the deletion is of maternal origin. suggestive of deletion of one allele. Analysis of the same blot with a probe for the proximally located D22S55 site, pH9118 (data not shown), gave a similar result with a single band of 5-5kb, again consistent with a deletion and suggesting that the loss of material from C22q extends proximal to the ASA gene at least as The production of ASA specific mRNA in the patient was tested using RT-PCR as described in Methods. Virtually no product was detectable in the child's sample although appropriate sized products were detected when primers for an unrelated gene (aspartylglucosaminidase) on another chromosome were used (data not shown). These results are consistent with the expectation of essentially no functional ASA specific mRNA where one allele is deleted and the other carries a major splicing mutation.
Discussion
We have reported here a case of a female patient with MLD who has inherited a paternal chromosome 22 carrying the infantile onset "I" allele and has a de novo constitutional ring chromosome 22 of maternal origin, deleted for the ASA gene. The deleterious "I-1" mutation is a splicing defect4 and is not expected to produce any active enzyme of functional mRNA. 
